Photo by impulsq from unsplash
To assess the noninferiority of the treat‐and‐extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in naïve patients with neovascular… Click to show full abstract
To assess the noninferiority of the treat‐and‐extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in naïve patients with neovascular age‐related macular degeneration (nAMD).
Keywords:
macular degeneration;
age related;
related macular;
treat extend;
neovascular age
Journal Title: Acta Ophthalmologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Acta Ophthalmologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!